Kliogest

Norethisterone Acetate and Estradiol, the active ingredients in Kliogest, are a combined oral contraceptive presented as a tablet for oral use. It is used to prevent pregnancy, manage menstrual disorders, and provide hormone replacement therapy for menopausal women.

GNH USA supplies Kliogest as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kliogest, a combined estrogen‑progestogen oral contraceptive, is indicated for several hormone‑related conditions.

- Prevention of pregnancy: provides reliable contraception for women of reproductive age. - Management of menstrual disorders: reduces irregular bleeding and alleviates dysmenorrhea. - Hormone replacement therapy: supplies estrogen and progestogen to relieve menopausal symptoms.

Kliogest may cause a range of adverse reactions. The most frequently reported events are generally mild and transient.

Common Side Effects: - Nausea - Headache - Breast tenderness - Spotting or breakthrough bleeding - Weight change - Mood swings

Serious or Rare Side Effects: - Venous thromboembolism (deep‑vein thrombosis, pulmonary embolism) - Stroke or transient ischemic attack - Myocardial infarction - Severe hypertension - Liver dysfunction or cholestasis - Allergic reactions, including anaphylaxis

Before prescribing Kliogest, clinicians should evaluate individual risk factors and counsel patients on safe use.

- Cardiovascular assessment: screen for hypertension, smoking, or a history of thromboembolic disease. - Age and smoking: avoid use in women over 35 who smoke. - Liver function: monitor patients with hepatic impairment. - Blood pressure monitoring: check regularly during therapy. - Patient education: advise on signs of VTE, stroke, or severe headache. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Kliogest can interact with several medicines, altering its effectiveness or increasing risk of adverse events.

Major Interactions (Avoid): - Rifampin and other strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, St. John’s wort) – may reduce contraceptive efficacy. - Certain antifungal agents (e.g., ketoconazole) – can increase hormone levels and risk of toxicity. - Griseofulvin – may diminish contraceptive protection.

Moderate Interactions (Monitor Closely): - Anticoagulants such as warfarin – may require INR monitoring. - Antidepressants (SSRIs, SNRIs) – potential for increased mood‑related side effects. - Antihypertensive drugs – may experience altered blood pressure control. - Anticonvulsants like valproate – may affect hormone metabolism. - Herbal supplements (e.g., ginseng) – possible impact on hormone levels.